Trials / No Longer Available
No Longer AvailableNCT00642057
Compassionate Use of Tetrabenazine in the Treatment of Abnormal Movements
Compassionate Use of Tetrabenazine in the Treatment of Hyperkinesias
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Joseph Jankovic · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Although the results of studies looking at tetrabenazine have shown its effectiveness in the management of hyperkinetic(too much) movement disorders, it has not been made available in the U.S. The drug must be obtained from Cambridge Laboratories, the distributor, using an individual IND (#16,161). The cost of the drug is passed on to the patient. The purpose of the protocol is to provide an efficacious drug, with few side effects, in an attempt to get rid of a variety of incapacitating dyskinesias (abnormal movements).
Detailed description
The purpose of the protocol is to provide compassionate use of an efficacious drug, with few side effects, in an attempt to get rid of a variety of incapacitating dyskinesias (abnormal movements).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | tetrabenazine | 25 mg titrated to optimal dose per patient |
Timeline
- First posted
- 2008-03-24
- Last updated
- 2023-03-24
Source: ClinicalTrials.gov record NCT00642057. Inclusion in this directory is not an endorsement.